BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2025 RESULTS

Financial Performance - Bio-Techne Corporation reported first quarter fiscal 2025 net sales of $289.5 million, representing a 5% increase compared to the same quarter last year, with organic revenue growth of 4% [2][7] - GAAP earnings per share (EPS) decreased to $0.21 from $0.31 in the prior year, while adjusted EPS increased to $0.42 from $0.41 [2][8] - GAAP operating income fell 28% to $40.0 million, resulting in a GAAP operating margin of 13.8%, down from 20.2% in the same quarter last year [7][8] Segment Performance - The Protein Sciences segment reported net sales of $204.5 million, remaining flat compared to $204.7 million in the same quarter last year, with an organic growth of 1% [9] - The Diagnostics and Spatial Biology segment achieved net sales of $83.2 million, a 14% increase from $72.8 million in the prior year, with organic revenue growth also at 14% [10] Management Commentary - The CEO highlighted strong execution in the Diagnostics & Spatial Biology segment and robust growth in the cell and gene therapy business, particularly in GMP reagent offerings [5] - The company expressed confidence in the recovery of the biotech end market, supported by favorable funding dynamics [5] Cash Flow and Financial Position - Cash and cash equivalents at the end of the quarter were $187.5 million, up from $151.8 million at the beginning of the period [31] - The company reported net cash provided by operating activities of $63.9 million, compared to $59.4 million in the same quarter last year [31]